Demodex

Leading with Clarity: BOSA Equips Eye Doctors for Booming Dry Eye Market

Retrieved on: 
Tuesday, January 16, 2024
OSD, Optometry, Eye, Patient, MD, Dry eye syndrome, Ophthalmology, Multimedia, Interferometry, Documentation, Telecanthus, Demodex, Disease, White, Therapy, Gland, OD, Education, M&S, Telescopic sight

NILES, Ill., Jan. 16, 2024 /PRNewswire-PRWeb/ -- M&S Technologies, a leader in computerized vision testing in collaboration with Bruder Healthcare, renowned for dry eye solutions announce the launch of the M&S Bruder Ocular Surface Analyzer (BOSA). The all-in-one innovative device represents an advancement in dry eye assessment and is poised to be a necessity for eye care practices treating ocular surface disease (OSD), including dry eye syndrome. In only 15 seconds per eye, BOSA captures and provides OSD test results. "With the system's unmatched speed, accuracy, and ease of use, doctors can manage dry eye patients more efficiently and effectively, improving outcomes through better data and boosting revenues through time savings," explains Brent Jones of Hilco Vision, parent company of M&S Technologies and Bruder Healthcare.

Key Points: 
  • The all-in-one innovative device represents an advancement in dry eye assessment and is poised to be a necessity for eye care practices treating ocular surface disease (OSD), including dry eye syndrome.
  • "The Bruder Ocular Surface Analyzer is the most comprehensive "one-stop" instrument available to document Dry Eye Disease."
  • BOSA consolidates these diverse tests into one efficient device, offering eye doctors a comprehensive solution within their exam rooms.
  • It is the answer for both the established Dry Eye practice looking to improve efficiency and the eye care practice looking to start a Dry Eye clinic," said Darrell White, MD of SkyVision Centers.

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

Retrieved on: 
Monday, December 11, 2023
Science, Food, BID, TID, Disease, Meibomian gland, TARS, Demodex, MGD, Patient, Pharmaceutical industry

Collarette cure and lid margin erythema cure results were also statistically significant and consistent with the results of previous TP-03 studies.

Key Points: 
  • Collarette cure and lid margin erythema cure results were also statistically significant and consistent with the results of previous TP-03 studies.
  • No statistically significant differences were observed between the BID and TID treatment arms and TP-03 was well tolerated.
  • “We are encouraged by these early results, which underscore the potential of TP-03 to address the underlying cause of disease,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
  • “We look forward to further analyzing the data from this trial and continued discussions with the U.S. Food and Drug Administration about the best path forward for TP-03 in MGD.”

LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
ESC, Bristol Myers Squibb, JAMA Cardiology, LIBRA, MITES, Clinical trial, Patient, Demodex, BMS, Congress, European Society of Cardiology, Pharmaceutical industry, Cardiology, Hong Kong

Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.

Key Points: 
  • Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.
  • In July 2023, LianBio entered into a clinical supply agreement with AstraZeneca in China to procure osimertinib for this clinical trial.
  • In October 2023, LianBio announced that the company’s Board of Directors initiated a comprehensive strategic review of the company, with an update anticipated in the first half of 2024.
  • Cash, cash equivalents, marketable securities and restricted cash at September 30, 2023 totaled $252.2 million compared to $302.4 million as of December 31, 2022.

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

Retrieved on: 
Thursday, November 9, 2023
DB, Food, Eyelid, MITES, Disease, American Academy, Patient, PPP, ECP, FDA, Science, Optometry, TARS, American Academy of Optometry, American Academy of Ophthalmology, PDUFA, Pharmaceutical industry, Demodex, Ophthalmology

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the third quarter ended September 30, 2023, and recent business achievements.

Key Points: 
  • Management to host conference call today, November 9, 2023, at 1:30 p.m. P.T.
  • IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the third quarter ended September 30, 2023, and recent business achievements.
  • Saturn-2 data were delivered as encore presentations at the American Academy of Optometry and American Academy of Ophthalmology conferences.
  • In the third quarter of 2023:
    The Company’s expansive disease education efforts continue to drive awareness among eye care providers (ECPs) and action in proactively diagnosing DB.

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Retrieved on: 
Monday, October 30, 2023
Demodex, LIBRA, Patient, MITES, Pharmaceutical industry, Mineral oil

SHANGHAI, China and PRINCETON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced topline results from the Phase 3 LIBRA clinical trial evaluating TP-03 in Chinese patients with Demodex blepharitis.

Key Points: 
  • SHANGHAI, China and PRINCETON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced topline results from the Phase 3 LIBRA clinical trial evaluating TP-03 in Chinese patients with Demodex blepharitis.
  • Results demonstrated statistically significant mite eradication in patients with Demodex blepharitis treated with TP-03 compared to vehicle (p
  • “I am highly encouraged by the results of the LIBRA trial, which demonstrate TP-03’s ability to drive statistically and clinically significant mite eradication in Chinese patients with Demodex blepharitis.”
    “We are pleased that the LIBRA trial demonstrated significant Demodex mite eradication, the primary etiology of Demodex blepharitis, as well as a favorable safety profile.
  • More information about the LIBRA trial can be found on http://www.chinadrugtrials.org.cn/index.html (CTR20220726) and http://www.clinicaltrials.gov (NCT05629390).

Exploring the Demodex Blepharitis Market: Clinical Viewpoints, Pipeline Evaluation, and Market Access Services | Disease Landscape Insights

Retrieved on: 
Monday, September 11, 2023
Infection, Pharma, Chalazion, Eyelash, Ocular rosacea, Signs and symptoms, Research, Inflammation, IgG4-related ophthalmic disease, Causes, Eyelid, DLI, Biological soil crust, Immune system, Growth, MITES, Ageing, Patient, Itch, Diagnosis, Stye, Meibomian gland dysfunction, Gland, FDA, R, Red, NIH, Skin, NME, Disease, Cosmetics, Agriculture, Medical device, Pharmaceutical industry, Demodex

Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.

Key Points: 
  • Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.
  • We at Disease Landscape Insights (DLI) aim to assist our clientele in understanding the characteristics of this disease and help them develop cutting edge treatment solutions.
  • Unlocking Insights into Demodex Blepharitis – From Research to Treatment Solutions, Dive Deeper into Managing this Eye Condition.
  • According to a data released by NIH, around 41% to 70% of the world's population are affected or highly prone to Demodex Blepharitis .

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

Retrieved on: 
Wednesday, September 6, 2023
Demodex, Pharmacy, TARS, Doctor of Philosophy, Science, MD, Patient, Pharmaceutical industry

The event marks the launch of XDEMVY™, which is now available at pharmacies nationwide for prescription.

Key Points: 
  • The event marks the launch of XDEMVY™, which is now available at pharmacies nationwide for prescription.
  • “We’re delighted to acknowledge this tremendous milestone at Nasdaq as we advance on the path to deliver XDEMVY to potentially millions of patients with Demodex blepharitis,” said Dr. Azamian.
  • “I’m grateful and proud of the Tarsus team and the support of our many partners and advisors who contributed to this momentous event for the organization.
  • I look forward to celebrating this occasion on behalf of Tarsus, the eye care community and patients.”
    The Closing Bell Ceremony will be broadcast live from the Nasdaq MarketSite Tower in New York City.

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Retrieved on: 
Thursday, August 24, 2023
Pharmacy, TARS, Inflammation, Doctor of Philosophy, Science, Blepharitis, MD, Patient, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Full, Disease, Pharmaceutical industry, Demodex

IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that XDEMVY™ (lotilaner ophthalmic solution) 0.25% is now available at pharmacies nationwide for prescription. The U.S. Food and Drug Administration (FDA) approved XDEMVY on July 24, 2023, for the treatment of Demodex blepharitis.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) approved XDEMVY on July 24, 2023, for the treatment of Demodex blepharitis.
  • “We are delighted that within weeks of FDA approval, XDEMVY is now available to millions of patients with Demodex blepharitis,” said Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman of Tarsus.
  • Demodex blepharitis is characterized by redness, inflammation, missing or misdirected eyelashes, itching along the eyelid base, and the presence of collarettes.
  • To learn more about XDEMVY, including the Full Prescribing Information, please visit xdemvy.com and follow XDEMVY on Facebook and Instagram .

LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
Demodex, LIBRA, ESMO, Clinical trial, NDA, Oxford Handbook of Clinical Medicine, European Society of Cardiology, Oncology, CCA, NSCLC, European Society for Medical Oncology, AstraZeneca, Congress, Gene amplification, Hospital, Patient, EGFR, COE, BMS, Growth, Shirin David, European Society of Gynaecological Oncology, PD-1, ESC, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Stomach, HCM, FGFR2, NMPA, ORR, Food, Pharmaceutical industry, Cryptocurrency

SHANGHAI, China and PRINCETON, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • SHANGHAI, China and PRINCETON, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the second quarter ended June 30, 2023.
  • In April 2023, LianBio announced topline results from the Phase 3 EXPLORER-CN trial evaluating mavacamten in Chinese patients with oHCM.
  • LianBio expects to launch mavacamten in Singapore and Macau in the fourth quarter of 2023.
  • LianBio plans to file NDAs to support mavacamten approval in Taiwan and Thailand in the fourth quarter of 2023.

What is dandruff? How do I get rid of it? Why does it keep coming back?

Retrieved on: 
Thursday, July 27, 2023
Louis-Charles Malassez, Hair, Selenium, Honey, Human, Food, Zinc, Demodex, Face, Enzyme, Immunity, Research, Cell, Inflammation, Scalp, Science, Coal, Gland, Oil, Physician, Risk, Time, Irritation, Ketoconazole, Tea tree oil, Growth, Bacteria, Health, Skin, Petroleum jelly, Tar, Wine, Cosmetics, Beer, Vaccine, Malassezia, Dandruff

Up to half of all adults have had this scalp condition at one point, so you’ll no doubt know about these skin flakes and the itchiness.

Key Points: 
  • Up to half of all adults have had this scalp condition at one point, so you’ll no doubt know about these skin flakes and the itchiness.
  • It can affect many aspects of people’s lives, such as how they socialise, how they style their hair, and what clothes they wear.
  • We don’t know for sure whether our ancestors were as bothered by it as much as we are today.

What causes dandruff?

    • The yeast feeds on sebum, the natural moisturiser secreted by your sebaceous glands to stop your skin drying out.
    • These glands are attached to every hair follicle and the hair provides a dark, sheltered micro-environment ideal for the yeast to flourish.
    • This causes the cells to cluster together, appearing as white flakes.

Why do I have dandruff?

    • This depends on a range of factors.
    • Other factors include your immunity, and external factors, such as which hair-care products you use.

How do I get rid of dandruff?

    • The shampoos most commonly contain the anti-fungal agent zinc pyrithione (ZnPT for short).
    • Other common anti-fungals in shampoos include selenium sulfide, ketoconazole and coal tar.
    • You can also treat dandruff with scalp masks and scrubs that help restore the scalp barrier, by reducing inflammation and irritation.

Why does my dandruff come back?

    • Our research focussing on zinc pyrithione-based products showed these shampoos reached the skin surface.
    • We found the zinc pythione seemed to target the top of the follicles rather than deep into the follicles.
    • Your shampoo’s active ingredient may not reach the yeast that causes your dandruff.

What about future treatments?

    • These might target how the yeast grows in a different way to current active ingredients.
    • These include pre-biotics (supplements or food for skin flora) or pro-biotics (products that contain skin flora).

In a nutshell

    • Hopefully, we can develop improved shampoos that better deliver the active ingredient to where it’s needed.
    • These are important for our immunity, including preventing more disease-causing microbes (pathogens) from moving in.
    • They also help the skin produce antimicrobial peptides (short proteins) that protect us from pathogens.